Compare WEYS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEYS | CTNM |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Apparel | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 416.1M |
| IPO Year | N/A | 2024 |
| Metric | WEYS | CTNM |
|---|---|---|
| Price | $34.18 | $11.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 17.0K | ★ 294.3K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $279,843,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.51 | $3.35 |
| 52 Week High | $38.24 | $15.25 |
| Indicator | WEYS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 52.45 |
| Support Level | $33.48 | $11.50 |
| Resistance Level | $34.44 | $12.00 |
| Average True Range (ATR) | 1.10 | 0.66 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 69.18 | 41.78 |
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.